Selected article for: "admission level and liver disease"
Author: Hao, Shao-Rui; Zhang, Shan-Yan; Lian, Jiang-Shan; Jin, Xi; Ye, Cheng-Yin; Cai, Huan; Zhang, Xiao-Li; Hu, Jian-Hua; Zheng, Lin; Zhang, Yi-Min; Jia, Hong-Yu; Yu, Guo-Dong; Wang, Xiao-Yan; Gu, Jue-Qing; Lu, Ying-Feng; Yu, Xiao-Peng; Yu, Liang; Xiang, Dai-Rong; Ye, Chan-Yuan; Jin, Ci-Liang; Qiu, Yun-Qing; Li, Lan-Juan; Sheng, Ji-Fang; Liang, Ting-Bo; Yang, Yi-Da
Title: Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study.
  • Cord-id: qdg9h2k2
  • Document date: 2020_7_1
    • ID: qdg9h2k2
    Snippet: INTRODUCTION Elevated liver enzyme levels are observed in patients with coronavirus disease 2019 (COVID-19); however, these features have not been characterized. METHODS Hospitalized patients with COVID-19 in Zhejiang Province, China, from January 17 to February 12, 2020, were enrolled. Liver enzyme level elevation was defined as alanine aminotransferase level >35 U/L for men and 25 U/L for women at admission. Patients with normal alanine aminotransferase levels were included in the control grou
    Document: INTRODUCTION Elevated liver enzyme levels are observed in patients with coronavirus disease 2019 (COVID-19); however, these features have not been characterized. METHODS Hospitalized patients with COVID-19 in Zhejiang Province, China, from January 17 to February 12, 2020, were enrolled. Liver enzyme level elevation was defined as alanine aminotransferase level >35 U/L for men and 25 U/L for women at admission. Patients with normal alanine aminotransferase levels were included in the control group. Reverse transcription polymerase chain reaction was used to confirm severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and patients symptomatic with SARS-CoV-2 infection were defined as patients with COVID-19. Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were collected and compared. RESULTS Of 788 patients with COVID-19, 222 (28.2%) patients had elevated liver enzyme levels (median [interquartile range {IQR}] age, 47.0 [35.0-55.0] years; 40.5% women). Being male, overweight, and smoking increased the risk of liver enzyme level elevation. The liver enzyme level elevation group had lesser pharyngalgia and more diarrhea than the control group. The median time from illness onset to admission was 3 days for liver enzyme level elevation groups (IQR, 2-6), whereas the median hospitalization time for 86 (38.7%) discharged patients was 13 days (IQR, 11-16). No differences in disease severity and clinical outcomes were noted between the groups. DISCUSSION We found that 28.2% of patients with COVID-19 presented with elevated liver enzyme levels on admission, which could partially be related to SARS-CoV-2 infection. Male patients had a higher risk of liver enzyme level elevation. With early medical intervention, liver enzyme level elevation did not worsen the outcomes of patients with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acute infection and adaptive mutation: 1
    • acute infection and admission course: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute infection and liver cirrhosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute infection and liver cirrhosis case: 1
    • acute infection and liver damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute infection and liver diseases: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute kidney injury and admission course: 1, 2, 3, 4, 5, 6, 7, 8
    • acute kidney injury and liver cirrhosis: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute kidney injury and liver cirrhosis case: 1
    • acute kidney injury and liver damage: 1, 2, 3, 4, 5, 6
    • acute kidney injury and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute kidney injury and liver diseases: 1, 2, 3, 4, 5, 6
    • acute respiratory distress syndrome and adaptive evolution: 1
    • acute respiratory distress syndrome and admission course: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory distress syndrome and liver cirrhosis: 1, 2, 3, 4, 5
    • acute respiratory distress syndrome and liver damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory distress syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and liver diseases: 1, 2, 3, 4, 5, 6